Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

28.81 -0.19 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Breaking Down Veracyte: 7 Analysts Share Their Views
Via Benzinga
Veracyte Announces First Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch 
Via Chartmill
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
Via Benzinga
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing? 
Via Chartmill
Demystifying Veracyte: Insights From 7 Analyst Reviews
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details. 
Via Benzinga
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Exploring NASDAQ:VCYT's high growth characteristics.
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. 
Via Chartmill
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
From Veracyte, Inc.
Via Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
From Veracyte, Inc.
Via Business Wire
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
5 Analysts Assess Veracyte: What You Need To Know
Via Benzinga
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
From Veracyte, Inc.
Via Business Wire
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit. 
Via Benzinga
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For February 24, 2025
Via Benzinga
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
From Veracyte
Via Business Wire
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.